Genentech expands deal with molecular glue biotech Orionis for $105M upfront

Lei Lei Wu

News Reporter

Roche’s subsidiary Genentech is signing a second deal with Orionis Biosciences to expand its search through the world of protein interactions in hopes of developing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Genentech expands deal with molecular glue biotech Orionis for $105M upfront

Lei Lei Wu

News Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Altos Labs buys anti-aging startup Dorian Therapeutics

Cocaine vaccine, a longshot attempt to quell cravings, yields mixed data in small study

Updated: Trump administration reveals 'most favored nation' drug price country targets

How PureTech’s lung fibrosis drug stacks up against the competition

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Genen­tech ex­pands deal with mol­e­c­u­lar glue biotech Ori­o­n­is for $105M up­front

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Genentech expands deal with molecular glue biotech Orionis for $105M upfront